Proactive Investors - Run By Investors For Investors

Shield Therapeutics CEO hails positive head-to-head Feraccru study results

Carl Sterritt, chief executive of Shield Therapeutics PLC (LON:STX), tells Proactive London's Andrew Scott that Feraccru, its iron deficiency drug, has proved itself to be just as good as the current standard of care treatment in a late-stage trial.

The year-long phase IIIb study confirmed Feraccru’s “non-inferiority” to Ferinject when it came to boosting patients’ haemoglobin (Hb) levels.

As part of its commercialisation agreement with Norgine BV, Shield will now receive a €2.5mln milestone payment.

 
Meet Location Sciences Group PLC, Itaconix Plc, Shield Therapeutics PLC and WideCells Group at our event, London , 21 March 2019. Register here »
View full STX profile View Profile

Shield Therapeutics PLC Timeline

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use